|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Concentration- dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans显示文摘 | FUCHS H TILLEMENT JP URIEN S | 2009 | J Pharm Pharmacol2009，61，1： | 1 |
| 2 | Role of lipopro teins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood显示文摘 | Lemaire M Tillement JP | 1982 | J Pharm Pharmacol1982，34，11： | 1 |
| 3 | A pharmacokinetic and pharmacodynamic modelling of the antihistaminic (H1)effects of cetirizine 显示文摘 | Urien S Tillement JP Ganem B | 1999 | Int J Clin Pharmacol Ther1999，37，10： | 1 |
| 4 | Prevention of cell damage in ischaemia: novel molecular targets in mitochon- dria 显示文摘 | Morin D Papadopoulos V Tillement JP | 2002 | Expert Opin Ther Targets2002，6，3： | 1 |
| 5 | Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine,two histamin H1-receptor antagonists显示文摘 | TILLEMENT JP TESTA B BREE F | 2003 | Biochem Pharmacol2003，66，7： | 1 |
| 6 | The Advantages for an H1 antihistamine of a low volume of distribution 显示文摘 | JP Tillement | 2000 | Allergy2000，55，： | 1 |
| 7 | Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid显示文摘 | Barre J Chamouard JM Houin G Tillement JP | 1985 | Clin Chem1985，31，： | 1 |
| 8 | Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans显示文摘 | Fuchs H Tillement JP Urien S | 2009 | J Pharm Pharmacol2009，61，1： | 1 |
| 9 | Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1 - receptor antagonists 显示文摘 | Testa B Bree F | 2003 | Biochem Pharmacol2003，66，7： | 1 |
| 10 | A pharmacokinetic and pharmacodynamic modeling of the antihistaminic ( H1 ) effect of cetirizine 显示文摘 | Urien S Tillement JP Ganem B | 1999 | Int JClinPharmacolTher1999，37，10： | 1 |
| 11 | Compared pharmacological haracteristics in humans of racemic cetirizine andlevocetirizine, two histamine H1-receptor antagonists 显示文摘 | Tillement JP Testa B Bree F | 2003 | Biochem Pharmacol2003，66，7： | 1 |
| 12 | Concentration- dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans显示文摘 | FUCHS H TILLEMENT JP URIEN S et ol | 2009 | J Pharm Pharmacol2009，61，1： | 1 |
| 13 | Compared pharmacological charac- teristics in humans of racemic cetirizine and levocetirizine, two histamine Hi-receptor antagonists 显示文摘 | Tillement JP Testa B Br6e F | 2003 | Biochem Pharmacol2003，66，7： | 1 |
| 14 | Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria显示文摘 | Salducci MD Chauvet-Monges AM Tillement JP | | 0，，01： | 1 |
| 15 | Trimetazidine reduces early and long-term effects of experimental renal warm ischemia: a dose effect study显示文摘 | Cau J Favreau F Tillement JP | 2008 | J Vasc Surg2008，47，4： | 1 |
| 16 | Prevention of cell damage in ischaemia: novel molecular targets in mitochondria显示文摘 | Morin D Papadopoulos V Tillement JP | 2002 | Expert Opin TherTargets2002，6，： | 1 |
| 17 | Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats显示文摘 | Giovannini L Stradi R Urien S Tillement JP | 1998 | Drugs Exp Clin Res1998，24，： | 1 |
| 18 | Concentration dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans显示文摘 | Fuehs H Tillement JP Urien S | 2009 | J Pbarm Pharmacol2009，61，1： | 1 |
| 19 | A pharmacokineticpharmacodynamic modelling of the antihistaminic ( H1 ) effects of cetirizine 显示文摘 | Urien S Tillement JP Ganem B | 1999 | Int J Clin Pharmacol Ther1999，37，10： | 1 |
| 20 | Systemic antifumgal agents, Drug interactions of clinical significance显示文摘 | Albengres E Le Louet H Tillement JP | 1998 | Drug Sef1998，18，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员